What is Teduglutide?
Teduglutide is a peptide medicine for short bowel syndrome with dependence on intravenous nutrition or fluids. It acts in a different pathway from GLP-1 medicines.
Biological role or research focus
GLP-2-related intestinal absorption.
Its short bowel syndrome context is different from GLP-1 appetite medicines.
Role reference: MedlinePlus · Teduglutide ↗
Names you may encounter
Gattex
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- GLP-2 analogue
- Main research area
- Intestinal absorption in short bowel syndrome
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Source: MedlinePlus · Teduglutide ↗
Quick answers
- Is Teduglutide FDA approved?
- Yes. Gattex (NDA 203441, approved December 2012) for short bowel syndrome in patients dependent on parenteral support. Source ↗
- Is Teduglutide safe?
- Teduglutide is a GLP-2 drug for short bowel syndrome; because it makes gut tissue grow, its label warns of polyps and tumor growth, bowel blockage, gallbladder and pancreas disease and fluid overload. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Teduglutide banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| STEPS (2012) | Human randomized trial | 86 patients with short bowel syndrome and intestinal failure requiring parenteral support. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2012
STEPS
Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure.
- Population / model
- 86 patients with short bowel syndrome and intestinal failure requiring parenteral support.
- Study design
- Twenty-four-week placebo-controlled study with protocol-guided support reductions.
- Main finding
- A reduction of more than 20% in support volume at weeks 20 and 24 occurred in 63% versus 30%. Mean weekly volume reduction was 4.4 versus 2.3 liters.
- Limits & context
- A response did not necessarily mean complete independence from IV support. The outcome is specific to intestinal failure, not general gut symptoms or appetite control.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
48 registered studies name Teduglutide as an intervention; 3 are recruiting or under way, 1 has not started recruiting yet, 41 completed and 3 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 48 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Definition, classification, and causes of short bowel syndrome. ↗
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2023 May · Journal Article, Review
Understanding short bowel syndrome: Current status and future perspectives. ↗
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · 2020 Mar · Journal Article, Review
Updates in Intestinal Failure Management. ↗
Journal of clinical medicine · 2025 Apr 28 · Journal Article, Review
Read available full text ↗
Teduglutide. ↗
· 2006 · Review
Risks & interactions
Teduglutide is a GLP-2 drug for short bowel syndrome; because it makes gut tissue grow, its label warns of polyps and tumor growth, bowel blockage, gallbladder and pancreas disease and fluid overload.
Safety is established by FDA labeling. Tumors appeared in rat and mouse cancer studies and polyps were seen in patients, so the label calls for regular colonoscopy checks. The label lists no contraindications; breastfeeding is not recommended.
Take extra care with: Heart or blood pressure problemsCancer, now or in the past
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Interactions
- Oral medicines, especially benzodiazepines or narrow-margin drugs: absorption may increase, raising side effects
Serious risks
- Faster growth of existing tumors, and intestinal polyps
- Intestinal or stoma blockage
- Gallbladder, bile duct and pancreas disease
- Fluid overload, including heart failure
Common side effects
- abdominal pain
- nausea
- upper respiratory infections
- abdominal bloating
- injection-site reactions
- vomiting
- fluid overload
- allergic reactions
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Gattex (teduglutide) prescribing information ↗
Key precautions
Intestinal polyps or malignancy history, obstruction symptoms, fluid overload, and gallbladder or pancreatic problems affect monitoring. Better absorption can also change exposure to oral medicines.
Source: MedlinePlus · Teduglutide ↗
Regulatory status
- U.S. FDA approval
- Approved
Gattex (NDA 203441, approved December 2012) for short bowel syndrome in patients dependent on parenteral support. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical uses & product context
Its medication reference describes short bowel syndrome requiring supplemental IV support. The study below evaluates a reduction in that support, not general gut comfort or weight loss.
Source: MedlinePlus · Teduglutide ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
Mechanism & research rationale
It promotes intestinal absorptive capacity. The key clinical question is whether patients can safely reduce the amount or frequency of parenteral support.
Source: MedlinePlus · Teduglutide ↗
Molecular structure
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- Its short bowel syndrome context is different from GLP-1 appetite medicines.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Does a trial response mean patients no longer needed IV support?
Not necessarily. The response threshold was a reduction in support volume, not complete independence.
Source: MedlinePlus · Teduglutide ↗
Is GLP-2 simply another name for GLP-1?
No. They are different signaling pathways with different therapeutic aims.
References & editorial record
- MedlinePlus · Teduglutide ↗
- Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
